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Available online 17 November 2016Background: Postoperative new-onset atrial ﬁbrillation (PNAF) is the most common complication following car-
diac surgery. The inﬂammatory response, as a potential underlying mechanism, has been extensively studied. In
small studies, the white blood cell count (WBC) has been shown to be the only consistent inﬂammatory marker
associated with PNAF. This study aimed to determine the association between perioperative WBC response and
PNAF in a larger study cohort.
Methods: Patients ≥18 years, undergoing elective cardiac surgery with a preoperative sinus rhythmwere includ-
ed. WBC was routinely measured preoperatively, and daily during the ﬁrst four postoperative days. Main out-
comes were the difference between peak postoperative WBC and neutrophil/lymphocyte ratio (N/L ratio) and
preoperative WBC and N/L ratio (ΔWBC and ΔN/L ratio respectively). Development of PNAF was evaluated in
all patients with continuous 12-lead ECG monitoring.
Results: 657 patients were included and 277 (42%) developed PNAF. Univariable analyses showed a statistically
signiﬁcant relationship betweenΔWBC (P=0.030) andΔN/L ratio (P=0.002), and PNAF. Inmultivariable anal-
ysis no signiﬁcant relationship was found between ΔWBC (OR: 1.14 per 1 × 109/L increase; 95% CI: 0.65–2.03;
P = 0.645), ΔN/L ratio (OR: 1.65 per 1 × 109/L increase; 95% CI: 0.94–2.90; P = 0.089), and PNAF. Increasing
age (OR: 1.08 per year; 95% CI: 1.01–1.16; P= 0.022) and (additional) valve surgery (versus CABG) (OR: 4.96;
95% CI: 2.07–6.91; P ≤ 0.001) were associated with PNAF.
Conclusions: The perioperative WBC response and its components were not associated with the development of
PNAF.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Postoperative new-onset atrialﬁbrillation (PNAF) is a frequent com-
plication after cardiac surgery. The reported incidence of PNAF in the lit-
erature varies from 25% to 40% after coronary artery bypass grafting
(CABG) and from 33% to 67% after complex valve surgery [1–3]. PNAF
is self-limiting in the majority of cardiac surgical patients. However, it
nearly always necessitates adjuvant medical management, and leads
to a prolonged length of hospital stay [1]. Associations between PNAF
and adverse outcomes, such as postoperative myocardial infarction,ability and freedom from bias of
Utrecht, Department of Cardio-
Heidelberglaan 100, 3508 GA
reland Ltd. This is an open access artiearly and latemortality, and decreased quality of life have been demon-
strated in several studies [1,4–9].
Despite the large number of studies that have investigated risk fac-
tors associated with PNAF after cardiac surgery, the etiology is still not
completely understood. Several studies have suggested that there is a
relationship between the perioperative inﬂammatory response to cardi-
ac surgery and PNAF [2,8,9]. Both the systemic inﬂammatory response
after cardiac surgery and the onset of PNAF peak 48–72 h after surgery
[9,10]. Nevertheless, the actual association between serum markers of
inﬂammation, such as C-reactive protein and several interleukins, and
PNAF is contradictory [9–11]. The only inﬂammatory biomarker that
has consistently been associated with PNAF in previous studies, is the
white blood cell count (WBC). A total of ﬁve previous studies have in-
vestigated the relationship between WBC and PNAF [12–16]. These
studies have included relatively small sample sizes (60–275 patients)
[12–16], while restricting inclusion criteria to patients aged above 60
(13), excluding any (additional) valve surgery [12–14,16] or patients
with moderate to signiﬁcant left ventricular dysfunction [15], or arecle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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some of these studies have used only one measurement in time of the
WBC [14] and none has corrected for hemodilution [12–16]. All the
above are risk factors that potentially inﬂuence and limit any observed
associations of PNAF and WBC. Therefore, the direct relationship be-
tween PNAF and the inﬂammatory response remains debatable.
The aim of this study was to investigate in detail the association be-
tween theperioperativeWBC response and PNAF in a large cohort of pa-
tients undergoing cardiac surgery.
2. Methods
2.1. Study design and population
This was a prospective observational study conducted in partici-
pants of the multicenter Dexamethasone for Cardiac Surgery (DECS)
study, which has been reported previously [17]. This trial compared
dexamethasone with placebo in patients undergoing elective cardiac
surgerywith cardiopulmonary bypass. For the current post-hoc analysis
of the aforementioned prospective study, we only used data from the
patients who were randomized to placebo in the University Medical
Center Utrecht (UMCU). Patients who were not in sinus rhythm preop-
eratively were excluded from the current analysis. The research ethics
committee approved the research protocol of the current study, and
waived the requirement for additional informed consent.
2.2. Operation technique
Amidline sternotomywas performed to achieve access to the heart.
Balanced anesthesia with a combination of intravenous opioids, muscle
relaxants and volatile anesthetics was used in all patients. Techniques
for cardioplegia, myocardial protection and cardiopulmonary bypass
(CPB) were standardized [17].
2.3. Data collection and outcome
Data on baseline patient demographics, cardiovascular risk factors,
surgical characteristics, medication use, need for transfusion, intra-
and postoperative ﬂuid intake and the incidence of PNAF, were all pro-
spectively collected as part of the Case Record Form for the DECS study
[17]. Also, as postoperative infection could be an important confounding
factor in the relationship betweenwhite blood cell count and PNAF, data
on the most common infections postoperatively, i.e. pulmonary,
catheter-related, urinary and wound infections were collected and
assessed in the multivariable model.
2.4. White blood cell count analysis
Blood sampleswere routinely taken at ﬁve different time points. The
ﬁrst time point comprised preoperative laboratory tests prior to sur-
gery. The WBC parameters measured closest to the time of surgery
were used for analysis. Postoperative blood samples were collected in
EDTA tubes at 24, 48, 72 and 96 h postoperatively. Routine blood cell
count analyses were performed using the Cell-Dynl Sapphire hematolo-
gy analyzer (Abbott Diagnostics, Santa Clara, CA, USA) [18]. For each
blood sample, all measured hematology parameters were stored in the
Utrecht Patient Oriented Database, including absolute cell counts data.
This database has been described in detail elsewhere, and is a relational
database platform which comprises all electronic clinical data from pa-
tients treated within the UMC Utrecht [18]. From these measurements,
pre- and postoperative total WBC, the N/L ratio and the differential
counts were derived.
For the analysis of the association between the perioperative WBC
response as a main indicator of inﬂammation, and PNAF, the changes
during the ﬁrst four postoperative days and the preoperative period in
each of the parameters were used. A maximum postoperative increasein WBC (ΔWBC) was deﬁned as the peak postoperative WBC
(maximum peak level during the ﬁrst four postoperative days) minus
the preoperative WBC. This was chosen above isolated preoperative or
postoperative values of WBC as a ΔWBC would illustrate the initiation
of an inﬂammatory response postoperatively in a more detailed
manner. In addition, components of the WBC response were subse-
quently calculated in the same manner, i.e. ΔN/L ratio, ΔNeutrophils,
ΔLymphocytes, ΔMonocytes, ΔEosinophils and ΔBasophils.
2.5. Outcomes
The occurrence of PNAF was evaluated in all patients using continu-
ous 12-lead ECG monitoring data, routinely collected during the ﬁrst
5 days postoperatively. Additional postoperative heart rhythm informa-
tion was obtained bymanually screening themedical records, intensive
care unit andward discharge letters, aswell as any additional postoper-
ative ECGs. Data collection was performed by an independent cardiolo-
gy resident who was blinded to other study data. To conﬁrm the
diagnosis of PNAF, at least one of the following criteria had to be met:
1) absence of P-waves in combination with irregular ventricular beats
for ≥10 s on a 12-lead ECG; 2) any type of PNAF (paroxysmal, persistent
or permanent); and 3) any therapeutic intervention performed for
PNAF (i.e. medication or cardioversion).
2.6. Statistical analysis
Univariable comparisons were made between patients who devel-
oped PNAF and patients who did not develop PNAF. Normality of con-
tinuous variables was checked using the Kolmogorov–Smirnov test.
Normally distributed variables are presented as means with standard
deviations (SD) and comparisons made using an independent Student
t-test. Data thatwere not normally distributed are presented asmedians
with interquartile range (IQR), and compared using aMann–Whitney U
test. Dichotomous characteristic variables are presented as absolute
numbers with percentages, and compared using the χ2-test. Correla-
tions between the main determinant ΔWBC and the variables age,
EuroSCORE, aortic cross clamp time, type of surgery, intra- and postop-
erative ﬂuid intake were assessed using the Spearman's rank test.
Multivariable logistic regression analysis was used to correct for the
effect of potential confounding factors. All baseline clinical and surgical
variables (Table 1) were considered potential confounders based on
previous literature and hencewere included in themultivariable logistic
regression model, along with the main aforementioned WBC parame-
ters preoperatively, i.e. total WBC, N/L ratio, neutrophils and lympho-
cytes. These baseline variables included demographics (age, gender
and body mass index), clinical variables (hypertension, diabetes
mellitus, left ventricular function, EuroSCORE, preoperative medica-
tion), intraoperative variables (surgery type, intraoperative bypass
and aortic cross clamp time), hemodilution parameters (need for trans-
fusion, intra- and postoperative ﬂuid intake), postoperative infection,
and the aforementioned preoperative WBC components. To make sure
that the assumptions of linearity of the logit and homoscedasticity
were valid in the model, a natural logarithm transformation was used
for variableswhichwere not normally distributed. Subsequently the fol-
lowing variables were transformed: EuroSCORE, CPB time, intra- and
postoperative ﬂuid intake, pre- and postoperative neutrophils and N/L
ratio and ΔN/L ratio. All variables were then forced entered in the mul-
tivariable logistic regression model. Interactions between two variables
that were hypothesized to interact and thus inﬂuence the relationship
between each of the interacting variables and PNAF, were also added
in the multivariable model. The subsequent model was analyzed and
the odds ratios (OR) alongwith 95% conﬁdence intervals were calculat-
ed for the remaining variables [19].
In a subset of patients, data on postoperative ﬂuid intake on the in-
tensive care unit (ICU)were known to be randomlymissing beforehand
(time period 2006–2008; 114 [17.5%] cases), since the DECS study
Table 1
Clinical, surgical and preoperative serum characteristics for the overall population as well as speciﬁcally for patients with and without PNAF. Data are shown as N (%) unless otherwise
speciﬁed.
Characteristics Study population N = 657 PNAF N = 277 No PNAF N = 380 P-value
Demographics
Age, mean (±SD), years 65.0 (11.4) 68.0 (10.4) 62.9 (11.7) b0.001
Male sex 461 (70.2) 191 (69.0) 270 (71.1) 0.561
BMI, mean (±SD), kg/m2 26.7 (4.1) 26.8 (4.3) 26.6 (4.0) 0.481
Coexistent medical conditions
Hypertension 367 (55.9) 156 (56.3) 211 (55.5) 0.84
Diabetes mellitus 120 (18.3) 54 (19.5) 66 (17.4) 0.486
Left ventricular function,a
Good 499 (76.0) 231 (76.9) 286 (75.3) 0.888
Poor 30(4.6) 12 (4.3) 18 (4.7) 0.806
EuroSCORE, median (IQR),b 4 (2–6) 5 (3–7) 4 (2–5) b0.001
Preoperative medication
Corticosteroid 33 (5.0) 10 (3.6) 23 (6.1) 0.157
Perioperative anti-arrhythmic drugs,c 343 (65.3) 155 (66.8) 188 (64.2) 0.527
Statins 184 (28.0) 81 (29.2) 103 (27.1) 0.612
Cardiac surgery type
Isolated CABG 311 (47.3) 94 (33.9) 217 (57.1) b0.001
Combined CABG and valve surgery,d 94 (14.3) 57 (20.6) 37 (9.7) b0.001
Valve surgery,d 346 (52.7) 183 (66.1) 163 (42.9) b0.001
Intraoperative parameters
CPB time, median (IQR), minute 92 (74–134) 104 (77–153) 86 (70–120) b0.001
AOX time, median (IQR), minute 70 (53–100) 81 (57–118) 65 (50–90) b0.001
Hemodilution parameters
Need for transfusion,e 212 (37.6) 96 (38.9) 116 (36.6) 0.58
Intraoperative ﬂuid intake, median (IQR), mL 3000 (2100–4000) 3000 (2100–4000) 3000 (2005–3900) 0.26
Postoperative ﬂuid intake up to 24 h after surgery, median (IQR), mL 3146 (2189–4442) 3211 (2313–4739) 3088 (2158–4314) 0.315
Preoperative WBC and components serum levels (×109)
Total WBC, mean (±SD) 7.8 (2.2) 7.8 (2.6) 7.7 (1.9) 0.762
Preoperative N/L ratio, median (IQR) 2.49 (1.84–3.48) 2.64 (2.02–3.60) 2.39 (1.77–3.39) 0.164
Neutrophils, mean (±SD) 4.9 (1.6) 4.9 (1.6) 4.9 (1.6) 0.757
Lymphocytes, mean (±SD) 2.0 (1.2) 2.0 (1.8) 2.0 (0.7) 0.976
Monocytes, mean (±SD) 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.385
Eosinophils, mean (±SD) 0.2 (0.2) 0.2 (0.2) 0.2 (0.2) 0.967
Basophils, mean (±SD) 0 (0) 0 (0) 0 (0) 0.374
Abbreviations: AOX: aortic cross clamp; BMI: bodymass index; CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass; CI: conﬁdence interval; EuroSCORE: European Sys-
tem for Cardiac Operative Risk Evaluation [25]; IQR, interquartile range; N: number; N/L ratio: neutrophil/lymphocyte ratio; OR: odds ratio; PNAF: postoperative new-onset atrial ﬁbril-
lation; SD: standard deviation; WBC: white blood cell count.
a Deﬁnition of left ventricular function classes [25]: good, ejection fraction of N50%, moderate, ejection fraction of 30%–50%; and poor, ejection fraction of b30%. Good left ventricular
function was analyzed versus moderate/poor function. Poor left ventricular function was analyzed versus good/moderate function.
b Higher EuroSCORE presents increased risk of perioperative mortality [25].
c Anti-arrhythmic drugs included B-blockers, amiodarone, digoxin and ﬂecainide.
d Valve surgery included aortic and/or mitral valve surgery. CABG analyzed versus valve surgery; combined CABG/valve surgery analyzed versus CABG or valve surgery alone; valve
surgery analyzed versus CABG.
e Transfusion included red blood cells, thrombocytes and/or fresh frozen plasma during the operation and the total length of intensive care stay.
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sive care unit. Consequently, we expected that the data on postoperative
ﬂuid intake to be missing at random, since these data were missing only
due to the period of inclusion. Conducting analyses on complete cases
only is however known to be prone to biased effect estimates. We there-
fore analyzed differences in baseline variables in cases with complete
data and in caseswithmissing values. Ifmajor differenceswere observed,
concluding that bias was potentially present, we attempted to reduce
that risk of bias by imputing those missing data for the variable “postop-
erative ﬂuid intake”, along with other few missing values of other base-
line variables (13 [1.8%] cases; totaling 127 (19.3%) cases with missing
values), using multiple imputation [20,21]. We used 20 imputation sets;
results of these separate imputation sets were pooled using Rubin's rule
to obtain correct estimates and standard errors [20,21]. To investigate
the effects of imputation on regression analysis, a sensitivity analysis in
cases with complete data were performed.
Throughout the analyses a two-sided P-value b0.05 was considered
statistically signiﬁcant. Statistical analyses were performed using SPSS
version 21.0 (IBM SPSS Statistics, Armonk, NY: IBM Corp).3. Results
3.1. Patient data
A total of 1565 patients were included in the DECS trial at the UMCU,
of which 781 were randomized to the placebo group. Of those, 657 pa-
tients were ultimately included in the primary analyses; 124 patients
had previous atrial ﬁbrillation (Fig. 1). Baseline characteristics of those
included are displayed in Table 1. Forty-two percent (N= 277) of pa-
tients developed PNAF. Characteristics of patients with any missing
data versus complete-case analysis are found in Supplementary
Table 1. Data were incomplete in a total of 127 (19.3%) patients and
were imputed.
No signiﬁcant differences were found in preoperative comorbidities
andmedication, need for transfusions, perioperative ﬂuid intake, preop-
erative total WBC, N/L ratio and differential counts between the two
groups. Patients who developed PNAF were older and underwent
more often (additional) valve surgery. Subsequently, the EuroSCORE
was higher, and cardiopulmonary bypass and aortic cross-clamping
Fig. 2. Course of postoperative peak of WBC (mean and standard error of the mean) at
baseline (0) and during the four consecutive postoperative days [1–4], in patients with
and without PNAF. *: P-value b0.05; PNAF: postoperative new-onset atrial ﬁbrillation;
WBC: white blood cell count.
Table 2
Differences (Δ) between maximum peak postoperative (highest serum value in ﬁrst 4
postoperative days) and preoperative WBC and leukocyte differentials for patients with
and without PNAF. Data are shown as mean number ×109/L (±SD) unless otherwise
speciﬁed.
Inﬂammatory marker PNAF N = 277 No PNAF N = 380 P-value
ΔWBC 7.1 (3.7) 6.5 (3.5) 0.030
ΔN/L ratio, median (IQR) 9.97 (6.33–18.67) 8.73 (5.37–13.23) 0.002
ΔNeutrophils 7.3 (3.4) 6.7 (3.2) 0.050
ΔLymphocytes −0.1 (0.7) −0.2 (0.5) 0.078
ΔMonocytes 0.7 (0.4) 0.6 (0.4) 0.285
ΔEosinophils 0 (0.2) 0 (0.2) 0.639
ΔBasophils 0 (0.1) 0 (0) 0.272
Abbreviations: IQR: interquartile range; N: number; N/L ratio: neutrophil/lymphocyte
ratio; PNAF: postoperative new-onset atrial ﬁbrillation; SD: standard deviation; WBC:
white blood cell count.
Fig. 1. Enrolment Flowchart. DECS: Dexamethasone for Cardiac Surgery; PNAF:
postoperative new-onset atrial ﬁbrillation; UMCU: University Medical Centre Utrecht.
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patients (6.1%) developed a postoperative infection episode.
3.2. White blood cell count and PNAF
The detailed course of the postoperative WBC is shown in Fig. 2.
The absolute numbers of ΔWBC, ΔN/L ratio along with the differ-
ences of the several differential counts and their association with
PNAF are presented in Table 2. In univariable logistic regression analy-
ses, solely a larger ΔWBC (OR: 1.03 per 1 × 109/L increase; 95% CI:
1.00–1.08; P = 0.030) and larger ΔN/L ratio (OR: 1.5 per 1 × 109/L
increase; 95% CI: 1.12–2.01; P = 0.002) were associated with PNAF.
Furthermore, detailed data on the maximum postoperative peak ofTable 3
Multivariable regression analysis for the risk of PNAF after cardiac surgery (N= 657).
Characteristic/variable Odds
Ratio
95% CI P-value
Age, per year 1.08 1.01–1.16 0.022
Male sex 1.09 0.57–2.08 0.806
BMI, per kg/m2 1.06 0.99–1.13 0.128
Hypertension 0.95 0.52–1.71 0.852
Diabetes Mellitus 1.51 0.71–3.22 0.29
Left ventricular function, poore 0.69 0.23–1.37 0.615
EuroSCORE 0.61 0.32–1.18 0.143
Preoperative use of corticosteroids 0.48 0.16–1.42 0.184
Perioperative anti-arrhythmic drugs,a 0.73 0.38–1.41 0.347
Preoperative statins 1.19 0.58–2.43 0.643
Valve Surgery,b 4.96 2.07–6.91 b0.001
CPB time, per minute,c 1.31 0.70–2.69 0.297
Need for transfusion,d 0.99 0.47–2.03 0.979
Intraoperative ﬂuid intake, per mL 1.06 0.55–2.06 0.859
Postoperative ﬂuid intake (≤24 h after surgery), per mL 1.17 0.68–2.03 0.575
Postoperative infection 0.81 0.24–2.69 0.73
Preoperative WBC 1.37 0.73–2.59 0.297
Preoperative N/L ratio 1.48 0.78–2.81 0.232
Preoperative neutrophils 0.79 0.48–1.97 0.438
Preoperative lymphocytes 0.65 0.28–1.52 0.45
ΔWBC 1.14 0.65–2.03 0.645
ΔN/L ratio 1.65 0.94–2.90 0.089
ΔNeutrophils 0.97 0.79–1.20 0.803
ΔLymphocytes 1.32 0.76–3.08 0.138
The odds ratios for all the inﬂammatorymarkers are per 1 × 109/L increase. Abbreviations:
AOX: aortic cross clamp; CI: conﬁdence interval; CPB: cardiopulmonary bypass;
EuroSCORE: European System for Cardiac Operative Risk Evaluation [25]; N/L ratio: neu-
trophil/lymphocyte ratio; PNAF: postoperative new-onset atrial ﬁbrillation; WBC: white
blood cell count.
a Anti-arrhythmic drugs included B-blockers, amiodarone, digoxin and ﬂecainide.
b Valve surgery included aortic and/ormitral valve surgery. Valve surgerywas analyzed
versus the control group, i.e. coronary artery bypass grafting (CABG).
c Only CPB time was added to the model and not AOX due to signiﬁcant
multicollinearity between both variables. CPB was chosen as it also comprises AOX.
d Transfusion included red blood cells, thrombocytes and/or fresh frozen plasma during
the operation and the total length of intensive care stay.
e Poor left ventricular function was analyzed versus good/moderate function.
975K.A. Jacob et al. / International Journal of Cardiology 228 (2017) 971–976WBCand the differential counts during theﬁrst four postoperative days,
as well as speciﬁcally on day 2, the highest incidence of PNAF, is
illustrated in Supplementary Tables 3–5.
No correlations were found between ΔWBC, and age (ρ=−0.041,
P= 0.307), EuroSCORE (ρ= 0.06, P= 0.138), aortic cross clamp time
(ρ=0.09, P=0.297), type of surgery (ρ=−0.042, P=0.30), intraop-
erative ﬂuid intake (ρ=0.03, P=0.457) and postoperative ﬂuid intake
(ρ = 0.03, P = 0.482). Interaction between variables which could be
correlated to each other and PNAF simultaneously, were also added to
the model. No signiﬁcant association was found between these
interactions (ΔWBC and Age, ΔWBC and ΔNeutrophils, ΔWBC and
ΔLymphocytes) and the presence of PNAF.
In the multivariable logistic regression analysis, no statistically sig-
niﬁcant relationship between a largerΔWBC (OR: 1.14 per 1 × 109/L in-
crease; 95% CI: 0.65–2.03; P=0.645),ΔN/L ratio (OR: 1.65 per 1 × 109/L
increase; 95% CI: 0.94–2.90; P=0.089), or the other differential counts
and PNAF remained present. Only older age (OR: 1.08 per year; 95% CI:
1.01–1.16; P = 0.022) and (additional) valve surgery (versus CABG)
(OR: 4.96; 95% CI: 2.07–6.91; P ≤ 0.001) remained associated with
PNAF (Table 3). The model did not violate the assumptions of linearity
of the logit and homoscedasticity. Interactions between variables,
were also added to the model. No signiﬁcant association was found be-
tween these interactions (ΔWBC and Age, ΔWBC and ΔNeutrophils,
ΔWBC and ΔLymphocytes) and the presence of PNAF.
To examinewhether the results of themultivariable regression anal-
ysis were different if no imputation was performed, the 127 patients
with incomplete data on postoperative ﬂuid intake and other baseline
values were excluded from analysis and a sensitivity analysis was
performed in the530 patients inwhich all datawas complete. Analyzing
results on complete cases only did not change our ﬁndings with respect
to the association between perioperative WBC response and PNAF
(Supplementary Table 2).4. Discussion
The present study has been the largest study to date to investigate
the association between perioperative WBC response and the develop-
ment of PNAF following cardiac surgery. This study shows that the peri-
operativeWBC response and its components are not associated with an
increased risk of PNAF.
Among the multitude of potential acute perioperative factors, the
postoperative inﬂammatory response has been postulated to play a sig-
niﬁcant role in the pathophysiology of PNAF. To this date, only theWBC,
and more speciﬁcally the N/L ratio, has consistently been shown to be
correlatedwith PNAF [9]. Nevertheless, the studies that have investigat-
edWBC as a risk factor for PNAF have only included small sample sizes,
have been limited to a single perioperative measurement of inﬂamma-
tory parameters or had restrictive inclusion criteria for patients; all of
which potentially inﬂuence and limit any observed associations of
PNAF and WBC [12–16].
In contrast to the aforestated studies, our study did not ﬁnd a rela-
tionship between PNAF and the perioperative WBC response and its
components. As this is by far the largest study to date, we believe that
it is reasonable to assume that the absence of an association is a true
negative ﬁnding. Thus, our results suggest thatWBC should be regarded
as no more than a general biological marker of inﬂammation postoper-
atively and hence not causally associated with PNAF. Our ﬁndings are
also in line with the negative results of several studies that have looked
at the effects of systemic anti-inﬂammatory drugs for the prevention of
PNAF [2,9,22]. The two largest trials, the Steroids In caRdiac Surgery
(SIRS) trial and the previously stated DECS trial, investigating the role
of methylprednisolone and dexamethasone respectively, found no pro-
tective value of glucocorticoids against PNAF after cardiac surgery [17,
23,24]. Henceforth, other non-inﬂammatory medication targeting
PNAF are recommended.A strength of our study is that it included a large and broad group of
cardiac surgical patients to focus on the association between PNAF and
the perioperativeWBC response and its components, enhancing general-
izability of the results. Also, the use of measurements of WBC at multiple
time points makes the results more robust. Furthermore, the risk for se-
lection bias in this study tends to be low. Patients were prospectively in-
cluded in the DECS trial and allocation to the placebo group was random
and well-concealed. Risk of selection bias due to selectively missing data
was further diminished by the use of multiple imputation. Our study is
also the ﬁrst to collect prospective data on multiple variables that could
have affected perioperative WBC, including need for blood transfusion
and total perioperative ﬂuid intake which are potential factors. Finally,
another strength is the detection of PNAF, as it was detected on continu-
ous postoperative 12-lead Holter monitoring for 5 days and the medical
records of all patients includedwere thoroughly examined,which further
increases the detection of any occurrence of PNAF.
4.1. Study limitations
Despite the above strengths, we acknowledge the following limita-
tions. As in all observational studies possible unmeasured confounding
could have played a role in this cohort study. This is a post-hoc analysis,
and PNAFwas a pre-speciﬁed secondary outcome and theWBC compo-
nents not pre-speciﬁed determinants at the time the original DECS
study was designed. However, all data were prospectively collected,
blood samples were taken at multiple time points and the incidence of
PNAF has been comprehensively investigated as is stated before. Sec-
ondly, postoperative ﬂuid intake data were only collected up to 24 h
after surgery, during intensive care unit stay. On the ward no data
were collected on ﬂuid intake. While this might have limited analyzing
hemodilution effects with regard to the concentrations of the WBC and
its components, one might argue that in cardiac surgical patients most
ﬂuid infusions take place during the ﬁrst 16 h after surgery with little
to no extra infusions on the ward afterwards.
5. Conclusions
In this large study on the relationship between the inﬂammatory
response after cardiac surgery and the development of PNAF, no associ-
ation was found between the postoperative WBC response and the
incidence of PNAF.
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